Arizona’s 2026 legislative session reflects a comprehensive effort to recalibrate the pharmacy regulatory landscape. In addition to sweeping PBM reform bills and amendments affecting the Arizona State Board of Pharmacy, lawmakers also introduced targeted legislation aimed at compounding practices, particularly those involving high-demand GLP-1 weight-management medications.
Although House Bill 4036 was withdrawn before advancing, its provisions signal heightened legislative scrutiny of GLP-1 compounding, bulk sourcing standards, quality control requirements, and advertising practices. For pharmacies engaged in compounding, the bill provides a preview of regulatory priorities that may resurface in future sessions.
House Bill 4036: GLP-1 Compounding with Bulk Drug Substances (Withdrawn)
Although no longer active, House Bill 4036 (HB 4036) warrants discussion because it signals legislative interest in the compounding space. The bill would have added a new section (A.R.S. § 32-1971.01) to the Board of Pharmacy’s statutes regulating the compounding and sale of drugs made from bulk drug substances that are GLP-1 receptor agonists or similar weight-management medications. However, the bill was withdrawn from the House Health & Human Services Committee before a vote.
Key provisions of HB 4036 would have required compounders to use pharmaceutical-grade bulk drug substances from FDA-registered and inspected establishments, conduct quality control testing, maintain records for at least two years, and include specific disclosures in any advertising for compounded medications. Violations would have been subject to civil penalties of $1,000 per dose and possible license or permit suspension or revocation. The legislative findings accompanying the bill cited concerns about foreign entities, including those in China, introducing inferior or contaminated active pharmaceutical ingredients into the compounding supply chain.
Impact on Community Pharmacies
Although withdrawn, HB 4036 signals that the Legislature is closely monitoring the compounding market, particularly around high-demand GLP-1 medications such as semaglutide and tirzepatide. Community pharmacies that engage in compounding should be aware that similar legislation may be reintroduced in the current or future sessions (whether in Arizona or in other states), potentially imposing significant new quality-control, sourcing, and advertising requirements on compounding operations.
Conclusion
Although HB 4036 did not advance, its introduction reflects a broader regulatory trend toward increased oversight of GLP-1 compounding and bulk drug-substance sourcing. State legislatures and Boards of Pharmacy nationwide are evaluating the intersection of federal FDA compounding guidance, drug shortages, and the rapid expansion of the GLP-1 weight-management market. Pharmacies engaged in compounding these medications should anticipate continued scrutiny and proactively strengthen sourcing protocols, quality-control procedures, documentation practices, and advertising review processes to mitigate enforcement risk and operational disruption.
How Frier Levitt Can Help
Frier Levitt advises pharmacies nationwide on compounding compliance, advertising review, regulatory risk assessments, and enforcement matters. As scrutiny of GLP-1 compounding increases, pharmacies should proactively evaluate sourcing, quality-control, and marketing practices to reduce regulatory exposure. If your pharmacy compounds GLP-1 medications or plans to enter this market, our attorneys can provide strategic guidance to help mitigate risk and prepare for evolving state-level regulation.
Read Article 1 of this series on 2026 Arizona Legislature Updates: Arizona’s 2026 PBM Reform Bills: Robust Amendments to Regulation and the Potential Impact for Community Pharmacies
Read Article 2 of this series on 2026 Arizona Legislature Updates: Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes
